skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Carcinogenesis tests of nickel arsenides, nickel antimonide, and nickel telluride in rats

Journal Article · · Cancer Invest.; (United States)

Carcinogenicity of nickel arsenides (NiAs, Ni/sub 11/As/sub 8/, Ni/sub 5/As/sub 2/, NiAsS), nickel antimonide (NiSb), and nickel telluride (NiTe) was tested by IM administration to male Fischer rats (14 mg Ni/rat). Three negative control groups received similar IM injections of glycerol vehicle, ferronickel alloy (NiFe), or nickel titanate (NiTiO/sub 3/); two positive control groups received nickel oxide (NiO) or ferronickel sulfide (Ni/sub 4/FeS/sub 4/) at equivalent dosages (14 mg Ni/rat). Within 2 years, the incidences of sarcomas at the injection site were: 0/20 (0%) in NiAs-treated rats, 8/16 (50%) in Ni/sub 11/As/sub 8/-treated rats; 17/20 (85%) in Ni/sub 5/As/sub 2/-treated rats; 14/16 (85%) in NiAsS-treated rats; 17/29 (59%) in NiSb-treated rats; and 14/26 (54%) in NiTe-treated rats. No local sarcomas occurred in the negative control groups, including 40 glycerol-treated rats, 16 NiFe-treated rats, and 20 NiTiO/sub 3/-treated rats; in the positive control groups, local sarcomas occurred in 14/15 (93%) of NiO-treated rats and 15/15 (100%) of Ni/sub 4/FeS/sub 4/-treated rats. The 99 sarcomas that were induced by the various nickel compounds included 67 rhabdomyosarcomas, 11 fibrosarcomas, 15 osteosarcomas, 1 fibrous histiocytic sarcoma, and 5 undifferentiated sarcomas; metastases were found in 57 sarcoma-bearing rats. Since Ni/sub 11/As/sub 8/, Ni/sub 5/As/sub 2/, and NiAsS are likely to be formed during oil shale retorting, environmental contamination by nickel arsenides in spent shale products could conceivably pose a carcinogenic hazard if large-scale production of petroleum from oil share is established.

Research Organization:
Univ. of Connecticut School of Medicine, Farmington
DOE Contract Number:
AC02-76EV03140
OSTI ID:
6133610
Journal Information:
Cancer Invest.; (United States), Vol. 1:6
Country of Publication:
United States
Language:
English